The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: EU Warns AstraZeneca Over Vaccine Delivery Delay

Mon, 25th Jan 2021 19:15

(Alliance News) - The EU issued an angry warning to pharmaceutical group AstraZeneca PLC on Monday over its unexpected delay in delivering millions of doses of its Covid-19 vaccine to the bloc.

The British-Swedish company's announcement "is not acceptable to the EU," EU Commissioner for health Stella Kyriakides said after a meeting of member state representatives and the firm.

"The EU will take any action required to protect its citizens and rights," she stressed.

Kyriakides did not elaborate on what action Brussels might take, but she said Brussels would propose a "transparency mechanism" to track shipments of vaccine exported from the EU to non-member countries.

The unusually blunt message underscored the threat facing the 27-nation EU as it tries to ramp up so far underpowered vaccination programmes as more contagious coronavirus variants threaten a looming third wave of the pandemic.

Last Friday, AstraZeneca said it would not meet its contractual delivery commitments to the EU because of unexplained "reduced yields" in its European supply chain.

That came a week after US group Pfizer Inc said it was also cutting early delivery volumes of its vaccine produced with German firm BioNTech SE.

Together, those announcements risk up-ending EU vaccination programmes that depend on people getting two jabs weeks apart. 

That would potentially trash European Commission chief Ursula von der Leyen's pledge made just a week ago to inoculate 70% of adults in the EU by the end of August.

The EU has currently authorised two vaccines for jabs: the BioNTech/Pfizer and Moderna Inc ones. 

By the end of this week it is poised to add the AstraZeneca vaccine, on the understanding that it would be already on hand and available for immediate roll-out.

Those vaccines, along with others also being vetted for marketing authorisation, were secured by the European Commission under advance purchase agreements on behalf of the EU and its 450 million residents.

Von der Leyen early Monday spoke with AstraZeneca's French CEO Pascal Soriot, and representatives EU member states held two meetings with the company to press for answers and a rapid solution meeting the contract terms.

"The answers of the company have not been satisfactory so far," Kyriakides said.

In a sign of distrust of the company she announced a move to have pharmaceutical companies notify EU authorities of vaccine exports out of the bloc, except for humanitarian deliveries.

"The Commission has today proposed to the 27 member states in the steering board that an export transparency mechanism will be put in place as soon as possible," she said.

She added: "The EU has pre-financed the development of the vaccine and its production and wants to see the return. The EU wants to know exactly which doses have been produced where by AstraZeneca so far, and if or to whom they have been delivered."

The only public statement by AstraZeneca on Monday was that Soriot was "pleased" to speak with von der Leyen and it "is doing everything it can to bring its vaccine to millions of Europeans as soon as possible".

In an effort to create enough time for vaccinations to protect the most vulnerable, the EU and various member states have increasingly restricted travel into the bloc and, for non-essential trips, within it.

On Monday, the European Commission urged further tightening of those rules, calling on member states to impose pre-trip PCR tests for all travellers allowed into the EU and quarantine on arrival if they came from zones where more-contagious virus variants were spreading.

It also recommended a heightened testing and quarantine regime, where possible, for essential travellers between – or even within – EU countries with high-risk areas classed as "deep red" by the European Centre for Disease Prevention and Control.

The EU Commissioner for justice, Didier Reynders, said the new variants with high infectivity – coming from former EU member Britain as well as South Africa and Brazil – meant "there is an urgent need to reduce the risk of travel-related infections to lessen the burden on overstretched healthcare systems".

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.